BRIEF-Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial

Reuters
Dec 08, 2025
BRIEF-Dyne <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Topline Results From Phase 1/2 Deliver Trial

Dec 8 (Reuters) - Dyne Therapeutics Inc DYN.O:

  • DYNE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 1/2 DELIVER TRIAL OF Z-ROSTUDIRSEN IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

  • DYNE THERAPEUTICS INC - REC SHOWS SIGNIFICANT INCREASE IN DYSTROPHIN EXPRESSION TO 5.46%

  • DYNE THERAPEUTICS INC: REGISTRATIONAL EXPANSION COHORT $(REC)$ MET PRIMARY ENDPOINT

  • DYNE THERAPEUTICS INC - SUBMISSION FOR U.S. ACCELERATED APPROVAL ON TRACK FOR Q2 2026

  • DYNE THERAPEUTICS INC - Z-ROSTUDIRSEN SHOWS FAVORABLE SAFETY PROFILE

Source text: ID:nGNX4dZKnL

Further company coverage: DYN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10